Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrology | 7 | 2024 | 260 | 3.010 |
Why?
|
| Kidney Diseases | 4 | 2024 | 2145 | 1.200 |
Why?
|
| Renal Dialysis | 6 | 2024 | 1780 | 0.920 |
Why?
|
| Hematuria | 2 | 2015 | 235 | 0.680 |
Why?
|
| Magnesium Deficiency | 1 | 2018 | 47 | 0.620 |
Why?
|
| Communication | 5 | 2024 | 3728 | 0.610 |
Why?
|
| Advance Care Planning | 2 | 2021 | 660 | 0.550 |
Why?
|
| Urolithiasis | 1 | 2015 | 131 | 0.470 |
Why?
|
| Fellowships and Scholarships | 3 | 2021 | 1066 | 0.430 |
Why?
|
| Physician-Patient Relations | 3 | 2016 | 3215 | 0.420 |
Why?
|
| Urologic Neoplasms | 1 | 2015 | 316 | 0.390 |
Why?
|
| Curriculum | 2 | 2021 | 3589 | 0.370 |
Why?
|
| Frail Elderly | 1 | 2014 | 691 | 0.340 |
Why?
|
| Palliative Care | 2 | 2021 | 3478 | 0.340 |
Why?
|
| Cryoglobulins | 1 | 2008 | 59 | 0.330 |
Why?
|
| Risk Management | 1 | 2012 | 571 | 0.320 |
Why?
|
| Erythropoietin | 1 | 2012 | 724 | 0.300 |
Why?
|
| Urologic Diseases | 2 | 2015 | 244 | 0.300 |
Why?
|
| Hyperparathyroidism | 1 | 2007 | 339 | 0.280 |
Why?
|
| Imidazolidines | 2 | 1999 | 39 | 0.270 |
Why?
|
| Lupus Nephritis | 1 | 2008 | 310 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 2536 | 0.250 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1581 | 0.240 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2275 | 0.200 |
Why?
|
| Staff Development | 1 | 2023 | 223 | 0.190 |
Why?
|
| Urinalysis | 3 | 2015 | 369 | 0.190 |
Why?
|
| Quality Improvement | 1 | 2016 | 3738 | 0.190 |
Why?
|
| Decision Making | 1 | 2014 | 3869 | 0.180 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 2195 | 0.180 |
Why?
|
| Faculty | 1 | 2023 | 383 | 0.180 |
Why?
|
| Calcinosis | 1 | 2007 | 1497 | 0.170 |
Why?
|
| Resuscitation Orders | 1 | 2020 | 267 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2018 | 94 | 0.150 |
Why?
|
| Health Communication | 1 | 2018 | 213 | 0.130 |
Why?
|
| Cystoscopy | 1 | 2015 | 134 | 0.130 |
Why?
|
| Algorithms | 1 | 2015 | 13853 | 0.120 |
Why?
|
| Glycosaminoglycans | 1 | 2007 | 624 | 0.120 |
Why?
|
| Albuminuria | 1 | 2007 | 683 | 0.120 |
Why?
|
| Penicillamine | 1 | 2013 | 59 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2023 | 5062 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 552 | 0.110 |
Why?
|
| Pilot Projects | 2 | 2023 | 8297 | 0.100 |
Why?
|
| Epoetin Alfa | 1 | 2012 | 83 | 0.100 |
Why?
|
| Chelating Agents | 1 | 2013 | 380 | 0.100 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2013 | 186 | 0.100 |
Why?
|
| Health Promotion | 1 | 2024 | 2194 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2013 | 23320 | 0.100 |
Why?
|
| Humans | 22 | 2024 | 742088 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 10163 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 1999 | 1205 | 0.090 |
Why?
|
| Inositol | 1 | 1990 | 216 | 0.090 |
Why?
|
| Kidney | 3 | 2008 | 7167 | 0.080 |
Why?
|
| Hematinics | 1 | 2012 | 281 | 0.080 |
Why?
|
| Critical Illness | 2 | 2020 | 2665 | 0.080 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 1990 | 494 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8621 | 0.080 |
Why?
|
| Complement C4 | 1 | 2008 | 257 | 0.080 |
Why?
|
| Critical Care | 1 | 2020 | 2640 | 0.080 |
Why?
|
| Gentamicins | 1 | 1988 | 253 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 713 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2008 | 343 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 2283 | 0.070 |
Why?
|
| Parathyroidectomy | 1 | 2007 | 235 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2007 | 2866 | 0.070 |
Why?
|
| Vancomycin Resistance | 1 | 2006 | 128 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 1988 | 405 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 198 | 0.060 |
Why?
|
| Patient Participation | 1 | 2014 | 1445 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1999 | 3336 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1990 | 1121 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 2505 | 0.060 |
Why?
|
| Prednisone | 1 | 2008 | 1567 | 0.060 |
Why?
|
| Interleukin-17 | 1 | 2008 | 900 | 0.050 |
Why?
|
| Vancomycin | 1 | 2006 | 500 | 0.050 |
Why?
|
| Hand | 1 | 2007 | 882 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 6608 | 0.050 |
Why?
|
| Urography | 1 | 2003 | 313 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2012 | 9144 | 0.050 |
Why?
|
| United States | 3 | 2021 | 69693 | 0.050 |
Why?
|
| Adult | 8 | 2020 | 213712 | 0.050 |
Why?
|
| Kidney Transplantation | 2 | 2013 | 4246 | 0.050 |
Why?
|
| Male | 11 | 2020 | 349538 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 1837 | 0.050 |
Why?
|
| Female | 10 | 2020 | 379592 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 12958 | 0.040 |
Why?
|
| Aldehyde Reductase | 1 | 1999 | 66 | 0.040 |
Why?
|
| Middle Aged | 9 | 2020 | 213127 | 0.040 |
Why?
|
| Imidazoles | 2 | 1999 | 1205 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 18355 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 1788 | 0.040 |
Why?
|
| Rats, Inbred Strains | 2 | 1990 | 2191 | 0.040 |
Why?
|
| Aged | 4 | 2020 | 162944 | 0.040 |
Why?
|
| Phorbols | 1 | 1977 | 43 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 1449 | 0.040 |
Why?
|
| Radiography | 1 | 2007 | 7010 | 0.040 |
Why?
|
| Cell Movement | 1 | 2008 | 5212 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2008 | 2099 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1977 | 821 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2016 | 53187 | 0.030 |
Why?
|
| Physicians | 1 | 2013 | 4554 | 0.030 |
Why?
|
| Vitamin D | 1 | 1988 | 3211 | 0.030 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2013 | 22 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 11695 | 0.030 |
Why?
|
| Cystinuria | 1 | 2013 | 19 | 0.030 |
Why?
|
| Risk Factors | 4 | 2013 | 72145 | 0.030 |
Why?
|
| Quality of Life | 1 | 2014 | 12730 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2008 | 10472 | 0.030 |
Why?
|
| Probability | 1 | 2007 | 2502 | 0.030 |
Why?
|
| Muscles | 1 | 1977 | 1617 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2007 | 2970 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1517 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 4982 | 0.020 |
Why?
|
| Salt Gland | 1 | 1989 | 5 | 0.020 |
Why?
|
| Organotin Compounds | 1 | 1989 | 6 | 0.020 |
Why?
|
| Dogfish | 1 | 1989 | 11 | 0.020 |
Why?
|
| Sharks | 1 | 1989 | 22 | 0.020 |
Why?
|
| Water Pollutants | 1 | 1989 | 26 | 0.020 |
Why?
|
| Chlorine | 1 | 1989 | 50 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 4929 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9963 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6365 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 3800 | 0.020 |
Why?
|
| Lipids | 1 | 1999 | 3302 | 0.020 |
Why?
|
| Heart Failure | 1 | 2012 | 10856 | 0.020 |
Why?
|
| Kidney Cortex | 1 | 1988 | 186 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 7153 | 0.020 |
Why?
|
| Risk | 1 | 1999 | 9679 | 0.020 |
Why?
|
| Prognosis | 2 | 2020 | 29010 | 0.020 |
Why?
|
| Phosphorus | 1 | 1988 | 338 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5310 | 0.020 |
Why?
|
| Bacteriolysis | 1 | 2006 | 51 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 7276 | 0.020 |
Why?
|
| Hemolysin Proteins | 1 | 2006 | 113 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 10943 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2008 | 1866 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 12017 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1999 | 8541 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1988 | 1791 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 1990 | 2167 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2018 | 4681 | 0.010 |
Why?
|
| Rats | 2 | 1990 | 24265 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 2749 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 13256 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 9941 | 0.010 |
Why?
|
| Smoking | 1 | 1999 | 8969 | 0.010 |
Why?
|
| Creatinine | 1 | 1988 | 1916 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1999 | 12695 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10232 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9305 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 1871 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 15530 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 1889 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1977 | 11470 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 4211 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1992 | 4393 | 0.010 |
Why?
|
| Bacteremia | 1 | 2006 | 962 | 0.010 |
Why?
|
| Survival Rate | 1 | 2013 | 12773 | 0.010 |
Why?
|
| Time Factors | 2 | 2013 | 40054 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2008 | 19223 | 0.010 |
Why?
|
| Research Design | 1 | 2013 | 5979 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2006 | 1398 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1977 | 297 | 0.010 |
Why?
|
| Actomyosin | 1 | 1977 | 111 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2007 | 62966 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 39004 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1990 | 6249 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 4379 | 0.010 |
Why?
|
| Myosins | 1 | 1977 | 409 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 57683 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 4438 | 0.010 |
Why?
|
| Culture Media | 1 | 1977 | 902 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1977 | 2255 | 0.010 |
Why?
|
| Mitochondria | 1 | 1988 | 3520 | 0.010 |
Why?
|
| Calcium | 1 | 1988 | 5753 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 8333 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3843 | 0.010 |
Why?
|
| Trimethyltin Compounds | 1 | 1989 | 1 | 0.010 |
Why?
|
| Veratrine | 1 | 1989 | 6 | 0.010 |
Why?
|
| Trialkyltin Compounds | 1 | 1989 | 6 | 0.010 |
Why?
|
| Cell Division | 1 | 1977 | 4564 | 0.010 |
Why?
|
| Proton-Translocating ATPases | 1 | 1989 | 116 | 0.010 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1989 | 179 | 0.010 |
Why?
|
| Animals | 3 | 1990 | 168561 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1989 | 393 | 0.000 |
Why?
|
| Diabetes Complications | 1 | 1992 | 1359 | 0.000 |
Why?
|
| Perfusion | 1 | 1989 | 1359 | 0.000 |
Why?
|
| Biological Transport | 1 | 1989 | 2119 | 0.000 |
Why?
|
| Tissue Donors | 1 | 1992 | 2205 | 0.000 |
Why?
|
| DNA | 1 | 1977 | 7289 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1989 | 1869 | 0.000 |
Why?
|
| Hypertension | 1 | 1992 | 8455 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1992 | 40955 | 0.000 |
Why?
|
| Child | 1 | 1992 | 77478 | 0.000 |
Why?
|
| Adolescent | 1 | 1992 | 85649 | 0.000 |
Why?
|
Concepts
(194)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(29)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_